Mechanism-based approach in designing patient-specific combination therapies for nonsense mutation diseases
2024

Designing Combination Therapies for Nonsense Mutation Diseases

publication Evidence: moderate

Author Information

Author(s): Bhat Saleem, Bhattacharya Arpan, Li Hong, Cui Xianon, Lueck John D., Goldman Yale E., Cooperman Barry S.

Primary Institution: University of Pennsylvania

Hypothesis

How do PTC identity and mRNA sequence context affect the catalytic activity of RFC in terminating peptide elongation?

Conclusion

The effectiveness of ataluren in stimulating readthrough of PTCs is strongly influenced by the mRNA sequence context.

Supporting Evidence

  • Ataluren has been conditionally approved for treating Duchenne muscular dystrophy in Europe.
  • PTC diseases account for approximately 12% of all human disease mutations.
  • Ataluren's effectiveness varies based on the sequence context of the PTC.

Takeaway

This study looks at how certain genetic mutations can stop protein production and how a drug called ataluren might help fix that by working better with certain genetic contexts.

Methodology

The study used an in vitro reconstituted system (PURE-LITE) and both ensemble and single molecule assays to analyze the effects of ataluren and other treatments on readthrough efficiency.

Limitations

The study primarily focuses on in vitro systems, which may not fully replicate in vivo conditions.

Digital Object Identifier (DOI)

10.1101/2024.11.13.623453

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication